AACR 2020

Tucatinib | Clinical Research | Abstract 3015/3

Tucatinib inhibits creatinine and metformin renal tubule secretion but has no effect on renal function (GFR)

Tucatinib | Preclinical Research | Abstract 4222/26

Tucatinib, a selective small molecule HER2 inibitor, is active in HER2 mutant driven tumors

Tucatinib | Clinical Research | Abstract 3016/4

Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers

Tucatinib | Preclinical Research | Abstract 1962/29

Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors

Enfortumab Vedotin | Urothelial Cancer | Abstract 5581/14

Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

SEA-CD40 | Preclinical Research | Abstract 5535/25

SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors

SGN-B6A | Preclinical Research | Abstract 2906/23

SGN-B6A: A new MMAE ADC targeting integrin beta-6 in multiple carcinoma indications

SGN-CD30C | Preclinical Research | Abstract 2889/6

SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies

SGN-CD228A | Preclinical Research | Abstract 2888/5

Utilizing PDX models to better understand factors that predict response to SGN-CD228A, an antibody drug-conjugate (ADC) for solid tumors

Research | Preclinical Research | Abstract 2895/12

Characterization of payload release from a novel camptothecin drug-linker